

## ASX Announcement

### Investor Webinar Recording Available

**Sydney Australia, 23 April 2025:** Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) (the **Company** or **Recce**), a leading developer of a New Class of Synthetic Anti-infectives is pleased to advise that a recording of the Company's webinar held on 22 April 2025 is now available.

A recording of the webinar can be found via the following link:

<https://www.youtube.com/watch?v=hOw3vtEXZ-w>

During the webinar, Managing Director and Chief Executive Officer, Mr James Graham, Executive Chairman, Dr John Prendergast, and Chief Medical Advisor and Non-Executive Director, Dr Alan W Dunton provided an update on recent clinical activities, the outlook for upcoming Phase 3 clinical trials and details of the recently announced AUD ~\$15.8 million Placement and Entitlement Offer that will support the upcoming clinical activities as Recce progresses towards commercialisation in 2026. The briefing was followed by a Q&A session.

**This announcement has been approved for release by the Recce Pharmaceuticals Board.**



**ASX:** RCE, **FSE:** R9Q

**Head Office:** Level 15, 1 Farrer Place, Governor Macquarie Tower, SYDNEY NSW 2000 **T** +61 (2) 9000 1907

**R&D Centre - Perth:** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

**Washington Office:** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA